Full Product Name
INF2 siRNA (Human)
Product Synonym Names
C14orf151; C14orf173; Inverted formin-2; HBEBP2-binding protein C
Product Gene Name
INF2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q27J81
Specificity
INF2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human INF2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of INF2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
INF2 sirna
siRNA to inhibit INF2 expression using RNA interference
Applications Tested/Suitable for INF2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for INF2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001026884.3
[Other Products]
NCBI GenBank Nucleotide #
NM_001031714.3
[Other Products]
UniProt Primary Accession #
Q27J81
[Other Products]
UniProt Secondary Accession #
Q27J83; Q69YL8; Q6P1X7; Q6PK22; Q86TR7; Q9BRM1; Q9H6N1[Other Products]
UniProt Related Accession #
Q27J81[Other Products]
Molecular Weight
25,954 Da
NCBI Official Full Name
inverted formin-2 isoform 2
NCBI Official Synonym Full Names
inverted formin, FH2 and WH2 domain containing
NCBI Official Symbol
INF2 [Similar Products]
NCBI Official Synonym Symbols
FSGS5; CMTDIE; pp9484; C14orf151; C14orf173
[Similar Products]
NCBI Protein Information
inverted formin-2
UniProt Protein Name
Inverted formin-2
UniProt Synonym Protein Names
HBEBP2-binding protein C
Protein Family
Inverted formin
UniProt Gene Name
INF2 [Similar Products]
UniProt Synonym Gene Names
C14orf151; C14orf173 [Similar Products]
UniProt Entry Name
INF2_HUMAN
NCBI Summary for INF2
This gene represents a member of the formin family of proteins. It is considered a diaphanous formin due to the presence of a diaphanous inhibitory domain located at the N-terminus of the encoded protein. Studies of a similar mouse protein indicate that the protein encoded by this locus may function in polymerization and depolymerization of actin filaments. Mutations at this locus have been associated with focal segmental glomerulosclerosis 5.[provided by RefSeq, Aug 2010]
UniProt Comments for INF2
INF2: Severs actin filaments and accelerates their polymerization and depolymerization. Defects in INF2 are the cause of focal segmental glomerulosclerosis type 5 (FSGS5). A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and edema. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. Defects in INF2 are the cause of Charcot-Marie-Tooth disease, dominant intermediate type E (CMTDIE). A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type E is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. Patients additionally manifest focal segmental glomerulonephritis, proteinuria, progression to end- stage renal disease, and a characteristic histologic pattern on renal biopsy. Belongs to the formin homology family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Unknown function
Chromosomal Location of Human Ortholog: 14q32.33
Cellular Component: perinuclear region of cytoplasm; endoplasmic reticulum; cytoplasm; nucleus
Molecular Function: Rho GTPase binding; actin binding
Biological Process: regulation of cellular component size; actin cytoskeleton organization and biogenesis
Disease: Focal Segmental Glomerulosclerosis 5; Charcot-marie-tooth Disease, Dominant Intermediate E
Research Articles on INF2
1. INF2 mutations are associated with focal segmental glomerulosclerosis.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
